Aspirin After Aortic Valve Repair
Yes, continue low-dose aspirin (75-100 mg daily) after aortic valve repair in patients without contraindications for oral anticoagulation. This recommendation is supported by current ACC/AHA guidelines and provides effective thromboprophylaxis with minimal bleeding risk 1.
Guideline-Based Recommendations
For Bioprosthetic Surgical Aortic Valve Repair/Replacement (SAVR)
Aspirin 75-100 mg daily is reasonable in the absence of other indications for oral anticoagulants (Class 2a recommendation) 1. This represents the standard approach for patients in sinus rhythm without atrial fibrillation or other anticoagulation indications.
Alternative Strategy: Short-Term Anticoagulation
For patients at low bleeding risk, vitamin K antagonist (VKA) therapy targeting INR 2.5 for 3-6 months followed by aspirin alone is also reasonable 1. However, this approach increases bleeding risk in the early postoperative period (16.7% vs 3.4% per patient-year with aspirin) without clear thromboembolism benefit 2.
Evidence Supporting Aspirin Monotherapy
Efficacy Data
Thromboembolic protection: Aspirin provides low thromboembolism rates (0.8% per patient-year) after aortic valve replacement, comparable to warfarin (2.9% per patient-year) 2
Bleeding safety: Aspirin demonstrates significantly lower bleeding complications compared to warfarin, particularly in the first 90 days postoperatively 2, 3
Long-term outcomes: Five-year actuarial freedom from thromboembolism reaches 95% with aspirin monotherapy, with minimal hemorrhagic complications (0.4% per patient-year) 4
Comparative Studies
A prospective study directly comparing warfarin versus aspirin after biological aortic valve replacement found no significant differences in cerebral ischemic events (3 events with aspirin vs 5 with warfarin in first 3 months), major bleeding, or survival 3. This challenges the theoretical advantage of early anticoagulation.
Special Considerations
Mechanical Valves (If Applicable)
If the repair involves mechanical components or prosthetic material requiring anticoagulation:
- Standard mechanical AVR: VKA targeting INR 2.5 (range 2.0-3.0) is mandatory 1
- On-X mechanical AVR (after 3 months): Lower INR target of 1.5-2.0 plus aspirin 75-100 mg may be reasonable in patients without thromboembolic risk factors 1, 5
Patients with Additional Antiplatelet Indications
When coronary artery disease or recent percutaneous coronary intervention creates competing indications, aspirin remains the foundation of therapy 1. Dual antiplatelet therapy should be guided by coronary considerations rather than valve-related factors.
Common Pitfalls to Avoid
Do not routinely use dual antiplatelet therapy (aspirin plus clopidogrel) after surgical aortic valve repair unless there is a separate coronary indication 1. This increases bleeding without reducing thromboembolism 6.
Do not use direct oral anticoagulants (DOACs) as substitutes for aspirin in routine post-valve repair management, as they lack evidence in this setting and may increase bleeding 1.
Do not discontinue aspirin prematurely - lifelong therapy is recommended unless contraindications develop 1.
Dosing Specifics
The recommended aspirin dose is 75-100 mg daily 1. This low-dose regimen provides adequate antiplatelet effect while minimizing gastrointestinal and bleeding complications compared to higher doses.